Can Cancer Treatment Cause Blood Clots? Current Scientific Facts
In this article
The Hidden Risk of Cancer Drugs: The Unseen Side of Clotting Events
Effects of anticancer therapies on the prothrombotic microenvironment: the vascular cost of lifesaving drugs in modern oncology.
Molecular Triggers of Drug-Induced Thrombosis
While targeting the tumor, cancer drugs can disrupt the biochemical balance that protects the vascular bed, or endothelial integrity. This causes clotting cells, platelets, and proteins, fibrinogen, to adhere to the vessel wall and create an obstruction.
Conventional chemotherapies such as cisplatin irritate the inner lining of blood vessels by directly burning it. This “vascular burn” activates the coagulation cascade within seconds.
While stimulating the immune system, immunotherapies (ICIs) can produce an uncontrolled wave of inflammation. Through a “cytokine storm,” this increases the rate of blood clotting.
2026 Data: Clotting Risk by Drug Class
Real-world evidence (RWE) indicates that the clot-promoting potential of some newer treatments is much higher than anticipated.
VTE (Blood Clot) Rates Observed Across Treatment Groups
These rates peak during the first 3 to 6 months of treatment. Drug-related clotting risk rises exponentially, particularly in pancreatic, stomach, and lung cancers.
Venous and Arterial Events: Two Different Threats
Anticancer drugs can affect not only veins (venous vessels) but also arteries (arterial vessels). This distinction is critical for protecting vital organs.
| Treatment Group | Venous Event (Leg / Lung) | Arterial Event (Stroke / Heart Attack) |
|---|---|---|
| Chemotherapy | Very High (15%+) | Low (1%) |
| Angiogenesis Inhibitors | Moderate | High (3-5%) |
| Anti-HER2 Therapies | Low | Risk of Cardiomyopathy |
A Closer Look: Silent Embolism and Catheter Risks
A clot does not always cause symptoms. Mild shortness of breath that develops suddenly in a patient with cancer is often mistaken for “disease-related fatigue,” yet it may reflect a small pulmonary embolism. Chemotherapy ports also create mechanical turbulence within blood vessels, providing an ideal setting for clot formation. Studies from 2026 identified unnoticed clots in 15% of patients with ports.
DROZDOGAN Academy Commentary
In cancer treatment, merely “killing the tumor” is no longer enough. Saving a patient from cancer only to lose them to a blocked blood vessel is an oncological defeat. In 2026, assigning every patient a “Clot Risk Score” at the start of treatment is now a necessity.
Conclusion: Particularly with high-risk drug regimens, anticoagulants (DOACs or LMWH) should be part of treatment. Healing means keeping all the body's systems working in harmony. Even the best drug cannot reach its target in a patient whose vascular route is blocked.
Scientific References
- 1. ESC Cardio-Oncology Guidelines. Vascular toxicity and management of cancer-associated thrombosis. 2026 Update.
- 2. The Lancet Haematology. Incidence of venous thromboembolism in patients treated with immune checkpoint inhibitors. March 2026.
- 3. JCO Cardio-Oncology. Arterial thromboembolic events associated with VEGF-targeting therapies: A global analysis.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.